RE:RE:RE:RE:90 daysRoche's Tecentriq and paclitaxel previously failed to improve outcomes for patients with PD-L1-positive metastatic TNBC in the IMpassion131 trial. That phase 3 setback, plus pressure from the FDA, led Roche to voluntarily withdraw its accelerated approval for Tecentriq in combination with Bristol Myers Squibb’s Abraxane, or nab-paclitaxel, in 2021.
Since 2021, ONCY has been able to demonstrate that pelareorep is able to convert an immunosuppressive and hypoxic TME to one that is conducive to PD-(L)1 immune checkpoint inhibition in patients with PD-(L)1 negative cancers, through the upreguation of PD-L1 receptors on cancer cells that is required for the effective activity of checkpoint inhibitors, like Tecentriq in combinatin with paclitaxel.